Researchers Identify New Target to Treat Lymphatic Filariasis
A new study reveals that inhibiting the BmMT protein effectively clears parasitic worms in animal models.
Updated on Oct. 25, 2026 in Diseases — General
Live Poll
Do you believe funding new drug research is the most effective way to improve global health?
Scientists have identified three inhibitors that successfully eliminate Brugia malayi worms in gerbils by targeting the BmMT protein. This breakthrough offers a potential new avenue for treating lymphatic filariasis, which currently impacts millions worldwide.
Why it matters
Lymphatic filariasis poses a significant health risk to hundreds of millions, and finding a novel target like BmMT provides a path toward developing effective new drugs. Because BmMT lacks orthologs in mammals, these inhibitors could potentially offer a safer treatment profile.
A preclinical study demonstrated that NSC56410 successfully eliminated microfilariae and adult worms in gerbils at a dose of 10 mg/kg/day. The inhibitors work by occupying over 80% of residues within the BmMT catechol substrate-binding fold.
The players
Brugia malayi
This is a species of filarial nematode parasite that is responsible for causing lymphatic filariasis in humans.
The details
The inhibitors function by blocking catecholamine binding within the nematode protein, causing a lethal accumulation of catecholamines in the worms. Researchers identified NSC177383, NSC133100, and NSC56410 as the primary lead compounds capable of eradicating the parasite in animal subjects.
Timeline
The research findings were published on October 25, 2026.
The Big Picture
This discovery updates the toolkit for the WHO Global Programme to Eliminate Lymphatic Filariasis by validating a new protein target for drug development. It extends current efforts to address the disease, which remains a threat to 885 million people across Asia and sub-Saharan Africa.
While this treatment remains in the research stage, it signifies progress toward future therapeutic options for individuals currently suffering from chronic lymphatic filariasis. Patients should continue to follow existing medical guidelines for managing the disease as these new drugs undergo further investigation.
The takeaway
Targeting nematode-specific proteins like BmMT is a promising strategy to overcome limitations in existing antifilarial therapies. Ongoing research into these inhibitors aims to move these compounds from the lab to effective clinical use.
Further reading
Learn more about advancements in global health by visiting our Diseases — General section.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe funding new drug research is the most effective way to improve global health?
